Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSC-833 and rIL-2 in Older Patients With Previously Untreated AML
NCT00003190Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 1998
- Primary completion
- Aug 2002
- Modality
- Cytokines & Interferons, Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of valspodar, aldesleukin in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Jan 1998; status: completed.
02
Drugs
valspodaraldesleukin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00003190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003190.